Literature DB >> 23459036

Urothelial carcinoma: vinflunine offers modest but important survival benefit.

Mina Razzak.   

Abstract

Entities:  

Year:  2013        PMID： 23459036     DOI： 10.1038/nrurol.2013.45

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.

Authors:  J Bellmunt; R Fougeray; J E Rosenberg; H von der Maase; F A Schutz; Y Salhi; S Culine; T K Choueiri
Journal:  Ann Oncol       Date:  2013-02-17       Impact factor: 32.976

2.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Authors:  Joaquim Bellmunt; Christine Théodore; Tomasz Demkov; Boris Komyakov; Lisa Sengelov; Gedske Daugaard; Armelle Caty; Joan Carles; Agnieszka Jagiello-Gruszfeld; Oleg Karyakin; François-Michel Delgado; Patrick Hurteloup; Eric Winquist; Nassim Morsli; Yacine Salhi; Stéphane Culine; Hans von der Maase
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544
  2 in total
  1 in total

1.  Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis.

Authors:  Karin Holmsten; Line Dohn; Niels Viggo Jensen; Carl-Henrik Shah; Fredrik Jäderling; Helle Pappot; Anders Ullén
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.